ClinicalTrials.gg
CompletedNCT01913379Updated Aug 1, 2013

Drug-drug Interaction Study With MDV3100 (ASP9785) and Gemfibrozil and Itraconazole

A Phase 1 interventional study of MDV3100 and Gemfibrozil in Healthy Subjects, Pharmacokinetics and Drug-Drug Interaction, sponsored by Astellas Pharma Europe B.V.. Completed at 1 site in France. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-08-01.

Sponsored by Astellas Pharma Europe B.V. (part of Astellas Pharma Inc) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

A study to assess possible drug-drug interactions between MDV3100 and gemfibrozil and MDV3100 and Itraconazole.

02

Conditions studied

  • Healthy Subjects
  • Pharmacokinetics
  • Drug-Drug Interaction

Keywords

  • Phase 1
  • MDV3100
  • Gemfibrozil
  • Itraconazole
  • Xtandi
  • enzalutamide
03

In context

Lead sponsor

Astellas Pharma Europe B.V. is the lead sponsor of 94 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight of at least 65.0 kg and no greater than 85.0 kg.
  • (BMI) of at least 18.5 and no greater than 30.0 kg/m2.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to MDV3100, itraconazole, gemfibrozil, any components of the formulations used, or any history of liver toxicity with other drugs.
  • Confirmed CYP2C8 PM status based on genotyping analysis.
  • Any of the liver function tests above the . A retest to confirm the result may be performed once.
  • History of seizure, including any febrile seizure, loss of consciousness, or transient ischemia attack within 12 months prior to enrollment (Day 1 visit), or any condition that may pre-dispose to seizure (e.g., prior stroke, brain arteriovenous malformation, head trauma with loss of consciousness requiring hospitalization).
  • Any history of asthma, eczema, any other allergic condition or previous severe hypersensitivity to any drug (excluding non-active hay fever).
  • Abnormal pulse and/or blood pressure (BP) measurements at the pre-study visit as follows: Pulse \<40 or >90 bpm; mean systolic BP >140 mmHg ; mean diastolic BP >90 mmHg (BP measurements taken in triplicate after subject has been resting in supine position for 5 min; pulse will be measured automatically).
  • A of >430 ms after repeated measurements (consistently after duplicate measurements), a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsades de pointes, structural heart disease, or a family history of Long QT Syndrome (LQTS).
  • Regular use of any inducer of metabolism (e.g. barbiturates, rifampin) in the 3 months prior to admission to the Clinical Unit.
  • Positive serology test for , anti HAV (IgM), anti- or anti- 1+2.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    1: MDV3100

    Drug: MDV3100

  • Experimental
    2: MDV3100 and gemfibrozil

    Drug: MDV3100 · Drug: Gemfibrozil

  • Experimental
    3: MDV3100 and itraconazole

    Drug: MDV3100 · Drug: Itraconazole

Interventions

06

What researchers measure

Primary outcomes

  1. Assessment of pharmacokinetic profile of MDV3100 by Cmax (Maximum concentration)

    Time frame: Day 1 through Day 53 (29 times)

  2. Assessment of pharmacokinetic profile of MDV3100 by AUCinf (AUC extrapolated to infinity)

    Time frame: Day 1 through Day 53 (29 times)

  3. Assessment of pharmacokinetic profile of MDV3100 by AUC0-432h (AUC from the time of dosing to 432 hours post-dose)

    Time frame: Day 1 through Day 53 (29 times)

Secondary outcomes

  1. Assessment of pharmacokinetic profile of MDV3100

    tmax (Time to attain Cmax), t1/2 (Apparent terminal elimination half life), Vz/F (Apparent volume of distribution during the terminal phase after extra vascular dosing) and CL/F(Apparent total body clearance after extra vascular dosing)

    Time frame: Day 1 through Day 53 (29 times)

  2. Assessment of pharmacokinetic profile of the metabolites MDPC0001 and MDPC0002

    Cmax, AUC0-432h, tmax, t1/2, and AUC0-inf

    Time frame: Day 1 through Day 53 (29 times)

  3. Assessment of metabolite-to-parent ratios for MDV3100

    This may additionally be reported to assess effects on particular enzyme pathways

    Time frame: Day 1 through Day 53 (29 times)

  4. Assessment of Gemfibrozil and gemfibrozil 1-O-β-glucuronide (Arm 2)

    Cmax, C0h, Cmin, tmax, AUCtau

    Time frame: Day 1 through Day 53 (50 times)

  5. Assessment of itraconazole and hydroxyitraconazole (Arm 3)

    Cmax, C0h, Cmin, tmax, AUCtau

    Time frame: Day 1 through Day 53 (50 times)

  6. Safety as assessed by recording adverse events, laboratory assessments, vital signs and electrocardiograms (ECGs)

    In arm 3, liver function tests (AST, ALT, GGT, total bilirubin) will be done regularly during itraconazole dosing

    Time frame: Day 1 through Day 53

07

Study locations

1 site
  • SGS
    Paris, 75015, France
08

References and documents

Publications

  • Gibbons JA, de Vries M, Krauwinkel W, Ohtsu Y, Noukens J, van der Walt JS, Mol R, Mordenti J, Ouatas T. Pharmacokinetic Drug Interaction Studies with Enzalutamide. Clin Pharmacokinet. 2015 Oct;54(10):1057-69. doi: 10.1007/s40262-015-0283-1. PubMed 25929560 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2013
First posted
Aug 1, 2013
Start
Aug 2011
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Last update
Aug 1, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01913379
Collaborators
Medivation, Inc.
Responsible party
Sponsor
First posted
Aug 1, 2013
Start date
Aug 2011
Primary completion
Dec 2011
Completion
Dec 2011
Last update
Aug 1, 2013

Study contacts

Operation Senior Research Manager
study chair · Astellas Pharma Europe B.V.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion